ZURICH (Reuters) – Swiss drugmaker Roche lifted its 2019 outlook on Wednesday, as sales growth in China and the United States outpaced price declines it has suffered amid President Donald Trump’s pressure on the industry to hold down charges.
FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann
Roche, the world’s biggest cancer drug maker, now sees mid single-digit revenue growth, up from the previous forecast of low- to mid-single digit growth. It sees core earnings per share mirroring sales growth.
Drugs division chief Bill Anderson said Roche’s drug revenue is soaring even as it honors a price-freeze pledge it made last year after Trump took to the phone and Twitter to urge companies